Clinical Trial Update: Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

The Phase 1 GMX1777 trial for refractory solid tumors or lymphomas has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomas
• Solid Tumors

Drugs mentioned

• GMX1777 (GMX1777)

Snippet

Sponsor: Gemin X | Conditions: Solid Tumors and Lymphomas | Phase 1 | Status: WITHDRAWN